Description:
Lorlatinib is an ATP-competitive ROS1/ALK inhibitor with potential antitumor activity. Lorlatinib binds to both ALK and ROS1 kinases, resulting in disruption of ALK- and ROS1-mediated signaling and inhibition of ALK- and ROS1-overexpressing tumor cells.
- Molecular Weight: 406.421
- Molecular Formula: C21H19FN6O2
Purity: ≥98%
Canonical SMILES:
CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
InChI:
InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
InChIKey: IIXWYSCJSQVBQM-LLVKDONJSA-N
- Boiling Point: 675.0±55.0 °C at 760 mmHg
- Melting Point: 184-187°C
- Appearance: White Solid
Synonyms:
PF06463922; PF 06463922; PF-06463922; PF-6463922; PF6463922; PF 6463922; Loratinib.
More details are to be found on supplier website
